+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Circulating forms of parathyroid hormone detected with an immunofluorometric assay in patients with primary hyperparathyroidism and in hyperparathyroidism secondary to chronic renal failure



Circulating forms of parathyroid hormone detected with an immunofluorometric assay in patients with primary hyperparathyroidism and in hyperparathyroidism secondary to chronic renal failure



Brazilian Journal of Medical and Biological Research 34(12): 1547-1550



In patients with uremia, intact parathyroid hormone (PTH) measurement appears to overestimate the biologically active hormone in circulation. The recent description of the accumulation in these patients of a non-intact PTH form measured by the standard immunometric assays, re-opened the question. In this study we submitted serum samples from 7 patients with primary hyperparathyroidism (PHP) and from 10 patients with hyperparathyroidism secondary to chronic renal failure (SHP) to preparative HPLC in order to discriminate the molecular forms measured by our currently used immunofluorometric assay for intact PTH. The elution profile obtained with the HPLC system showed two clearly defined peaks, the first one corresponding to a lower molecular weight form, and the second to the intact PTH (1-84) form. In patients with SHP the area under the curve for the first peak (mean 29.5%, range 20.6 to 40.4%) was significantly greater than that observed for patients with PHP (mean 15.6%, range 5.6 to 21.9%). This confirms previous studies showing accumulation of molecular forms of slightly lower molecular weight, presumably PTH (7-84), in patients with SHP and, to a lesser extent, in patients with PHP. The real necessity of assays that discriminate between these two molecular forms is debatable.

(PDF emailed within 1 workday: $29.90)

Accession: 010324652

Download citation: RISBibTeXText

PMID: 11717707


Related references

Characterization of the molecular forms of immunoreactive parathyroid hormone in primary hyperparathyroidism and in hyperparathyroidism due to renal failure. Scandinavian Journal of Clinical and Laboratory Investigation 43(7): 553-564, 1983

Circulating molecular forms of parathyroid hormone in primary and secondary hyperparathyroidism. Brazilian Journal of Medical and Biological Research 22(8): 963-965, 1989

Tertiary hyperparathyroidism after renal transplantation--report of two cases and comparative study of parathyroid function with secondary hyperparathyroidism in chronic renal failure. Transplantation Proceedings 26(4): 2167-2169, 1994

Radioimmunologic determination of circulating parathyroid hormone in patients with primary and secondary hyperparathyroidism. Minerva Medica 73(48): 3425-3428, 1982

Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. Journal of Clinical Endocrinology and Metabolism 54(1): 172-179, 1982

Heterogeneity of carboxyl-terminal parathyroid hormone circulating forms in patients with hyperparathyroidism due to end stage renal disease. Arquivos Brasileiros de Endocrinologia E Metabologia 53(9): 1074-1078, 2010

Effect of renal function on renal responsiveness to parathyroid hormone in primary hyperparathyroidism and chronic renal failure. European Journal of Clinical Investigation 15(1): 38-44, 1985

Radioimmunoassay of carboxyl and amino terminal fragments of parathyroid hormone for the evaluation of secondary hyperparathyroidism in chronic renal failure. Brazilian Journal of Medical and Biological Research 23(3-4): 235-243, 1990

Polymorphism of parathyroid glands in patients with chronic renal failure and secondary hyperparathyroidism. Endocrinologia Japonica 30(4): 463-468, 1983

Value of Intraoperative Parathyroid Hormone Assay during Parathyroidectomy in Dialysis and Renal Transplant Patients with Secondary and Tertiary Hyperparathyroidism. Nephron 138(2): 119-128, 2017

Immunoreactive forms of circulating parathyroid hormone in primary and ectopic hyperparathyroidism. Journal of Clinical Investigation 54(1): 175-181, 1974

Skeletal resistance to the calcaemic action of parathyroid hormone in uraemia: a mechanism for the hypocalcaemia and secondary hyperparathyroidism of chronic renal failure. Clinical Endocrinology 5 Suppl: 317s-325s, 1976

Cimetidine and primary hyperparathyroidism: failure of reduction of blood levels of parathyroid hormone in 5 cases of primary hyperparathyroidism. La Clinica Terapeutica 98(1): 63-68, 1981

Treatment of secondary hyperparathyroidism in patients with chronic renal failure by total parathyroidectomy and parathyroid autograft. Annals of Surgery 193(6): 777-793, 1981

Immunomodulatory effects of secondary hyperparathyroidism on circulating CD4+ and CD8+ T-lymphocytes in chronic renal failure patients. Egyptian Journal of Immunology 16(2): 71-82, 2012